c107895.htm - Generated by SEC Publisher for SEC Filing

 

 

 

 


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549
 

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

February 1, 2013

________________

 

        NOVO NORDISK A/S        
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

 

 


 

 

logo.gif

 

Trading in Novo Nordisk shares by board members, executives and associated persons on 31 January 2013

Bagsværd, Denmark, 1 February 2013 - In accordance with Section 28a of the Danish Securities Trading Act, Novo Nordisk is required on a daily basis to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons as reported by those persons to Novo Nordisk.

Please find below a statement of such trading in shares issued by Novo Nordisk.

 

Name

Mads Krogsgaard Thomsen

Reason for reporting

Chief Science Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Donation of shares (gift)

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

165 shares

Total value of transaction

DKK 167,888

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 6626

24 25 67 90

 

 

 

Company announcement No 9 / 2013

           

 


 

 

Page 2 of 11

 

Name

Sebastian Krogsgaard Gudnason

Reason for reporting

Associated to a member of Executive

Management, Mads Krogsgaard Thomsen

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Receipt of shares (gift)

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

55 shares

Total value of transaction

DKK 55,963

 

 

Name

Signe Krogsgaard Gudnason

Reason for reporting

Associated to a member of Executive

Management, Mads Krogsgaard

Thomsen

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Receipt of shares (gift)

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

55 shares

Total value of transaction

DKK 55,963

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 6626

24 25 67 90

 

 

 

Company announcement No 9 / 2013

           

 


 

 

Page 3 of 11

 

Name

Søren Sloth Thomsen

Reason for reporting

Associated to a member of Executive

Management, Mads Krogsgaard

Thomsen

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Receipt of shares (gift)

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

55 shares

Total value of transaction

DKK 55,963

 

As from 2004, members of Novo Nordisk's Executive Management and other members of the Senior Management Board have participated in a long-term share-based incentive programme where a proportion of the calculated shareholder value creation has been allocated to a joint pool for the participants. For 2009, 177,066 shares were allocated to the joint pool and the market value of the scheme was expensed in the accounts for 2009. In accordance with the principles of the programme, the Board of Directors of Novo Nordisk A/S on 30 January 2013 evaluated that the conditions for release of the joint pool of shares have been fulfilled.

Accordingly, the shares in the joint pool were transferred to 28 current and former members of senior management on 31 January 2013.

 

Name

Lars Rebien Sørensen

Reason for reporting

Chief Executive Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Other transaction (transfer of shares in

accordance with long-term incentive

programme)

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

15,764 shares

Total value of transaction

0 (transferred in accordance with the

long-term incentive programme for

2009)

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 6626

24 25 67 90

 

 

 

Company announcement No 9 / 2013

           

 


 

 

Page 4 of 11

 

Name

Lars Rebien Sørensen

Reason for reporting

Chief Executive Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Sale of shares

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

5,764 shares

Total value of transaction

DKK 5,879,683

 

 

Name

Jesper Brandgaard

Reason for reporting

Chief Financial Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Other transaction (transfer of shares in

accordance with long-term incentive

programme)

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

10,501 shares

Total value of transaction

0 (transferred in accordance with the

long-term incentive programme for

2009)

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 6626

24 25 67 90

 

 

 

Company announcement No 9 / 2013

           

 


 

 

Page 5 of 11

 

Name

Jesper Brandgaard

Reason for reporting

Chief Financial Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Sale of shares

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

4,500 shares

Total value of transaction

DKK 4,592,894

 

 

Name

Lars Fruergaard Jørgensen

Reason for reporting

Chief Information Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Other transaction (transfer of shares in

accordance with long-term incentive

programme)

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

5,250 shares

Total value of transaction

0 (transferred in accordance with the

long-term incentive programme for

2009)

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 6626

24 25 67 90

 

 

 

Company announcement No 9 / 2013

           

 


 

 

Page 6 of 11

 

Name

Lars Fruergaard Jørgensen

Reason for reporting

Chief Information Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Sale of shares

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

3,000 shares

Total value of transaction

DKK 3,061,930

 

 

Name

Lise Kingo

Reason for reporting

Chief Staff Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Other transaction (transfer of shares in

accordance with long-term incentive

programme)

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

10,501 shares

Total value of transaction

0 (transferred in accordance with the

long-term incentive programme for

2009)

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 6626

24 25 67 90

 

 

 

Company announcement No 9 / 2013

           

 


 

 

Page 7 of 11

 

Name

Lise Kingo

Reason for reporting

Chief Staff Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Sale of shares

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

3,501 shares

Total value of transaction

DKK 3,573,272

 

 

Name

Jakob Riis

Reason for reporting

Executive Vice President

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Other transaction (transfer of shares in

accordance with long-term incentive

programme)

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

5,250 shares

Total value of transaction

0 (transferred in accordance with the

long-term incentive programme for

2009)

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 6626

24 25 67 90

 

 

 

Company announcement No 9 / 2013

           

 


 

 

Page 8 of 11

 

Name

Jakob Riis

Reason for reporting

Executive Vice President

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Sale of shares

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

5,250 shares

Total value of transaction

DKK 5,355,368

 

 

Name

Kåre Schultz

Reason for reporting

Chief Operating Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Other transaction (transfer of shares in

accordance with long-term incentive

programme)

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

10,501 shares

Total value of transaction

0 (transferred in accordance with the

long-term incentive programme for

2009)

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 6626

24 25 67 90

 

 

 

Company announcement No 9 / 2013

           

 


 

 

Page 9 of 11

 

Name

Kåre Schultz

Reason for reporting

Chief Operating Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Sale of shares

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

3,525 shares

Total value of transaction

DKK 3,595,747

 

 

Name

Mads Krogsgaard Thomsen

Reason for reporting

Chief Science Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Other transaction (transfer of shares in

accordance with long-term incentive

programme)

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

10,501 shares

Total value of transaction

0 (transferred in accordance with the

long-term incentive programme for

2009)

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 6626

24 25 67 90

 

 

 

Company announcement No 9 / 2013

           

 


 

 

Page 10 of 11

 

Name

Mads Krogsgaard Thomsen

Reason for reporting

Chief Science Officer

Financial instrument and ID code

Novo Nordisk B DK006010261

Type of transaction

Sale of shares

Date of transaction

31 January 2013

Place of transaction

NASDAQ OMX Copenhagen

Volume of transaction

4,750 shares

Total value of transaction

DKK 4,848,055

 

Definitions and background information:

Publication

Publication shall take place the day after Novo Nordisk receives sufficient information on the trading. Publication is only required when the total amount of transactions of a specific board member/executive and his/her associated persons in any one calendar year has reached 5,000 euros.

Who are board members, executives and associated persons?

Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) relatives defined as brothers, sisters, parents, grandparents etc, children, grandchildren etc who have shared the same household with a board member/executive for at least one year, and 4) any legal person, including a company, a foundation or a partnership, which is controlled directly or indirectly by a board member/executive and/or a person mentioned in 1)–3), or to which a board member/executive and/or a person mentioned in 1)–3) has managerial responsibilities or economic interests substantially equivalent to the legal person.

What is trading/transaction?

Trading is any kind of transaction, including shares purchased or otherwise acquired, shares sold or otherwise disposed, gifts, mortgages and grants and exercise of options, but not heritage.

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 6626

24 25 67 90

 

 

 

Company announcement No 9 / 2013

           

 

 


 

 

Page 11 of 11

What is financial instrument and ID code?

Financial instrument includes shares listed on the NASDAQ OMX Copenhagen and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees. The ID code is the code (ISIN DK006010261) of the Novo Nordisk share on the NASDAQ OMX Copenhagen or the code (NVO) on New York Stock Exchange.

What is date and place of transaction?

Date of transaction is the actual transaction date. The place of transaction is the actual place of transaction, ie NASDAQ OMX Copenhagen or New York Stock Exchange.

What is volume and value of transaction?

The volume of transaction is the number of shares (of DKK 1 nominal value) or other financial instruments traded. The transaction value is the number of shares traded multiplied by the transaction price. The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.  

 

Further information

 

 

Media:

 

 

Anne Margrethe Hauge

+45 4442 3450

amhg@novonordisk.com

Ken Inchausti (US)

+1 609 514 8316

kiau@novonordisk.com

 

Investors:

 

 

Kasper Roseeuw Poulsen

+45 4442 4303

krop@novonordisk.com

Frank Daniel Mersebach

+45 4442 0604

fdni@novonordisk.com

Lars Borup Jacobsen

+45 3075 3479

lbpj@novonordisk.com

Jannick Lindegaard (US)

+1 609 786 4575

jlis@novonordisk.com

 

 

Novo Nordisk A/S

Novo Allé

Telephone:

Internet:

Investor Relations

2880 Bagsværd

+45 4444 8888

www.novonordisk.com

Denmark

Telefax:

CVR no:

 

+45 4444 6626

24 25 67 90

 

 

 

Company announcement No 9 / 2013

           

 

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: February 1, 2013

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer